Saving children's lives
Medicine formulated for childrenExternal Relations team
To speak with us about investing in MMV, please contact Andrea Lucard, Executive Vice-President, External Relations | +41 22 799 4588.
Invest in us
Why invest in MMV?
- We supported the development and final launch in 2009, of Coartem® Dispersible, the first affordable, high quality paediatric ACT for use in Africa.
- MMV's innovative antimalarial pipeline contains over 65 cutting-edge projects and targets the eradication of malaria.
- MMV leverages public and private financial resources, world-class expertise and facilities, with over 130 partners globally.
More new drugs are essential if we are to defeat malaria. With your funding, we can succeed!
Why invest in malaria?
Of the one million malaria deaths each year, 90% occur in Africa. We aim to help defeat malaria and prevent millions of unnecessary deaths.
Why invest in R & D?
New, effective medicines are essential weapons in the integrated effort to eradicate malaria. Our pipeline of new innovative antimalarials will develop these.
Why invest in access and delivery?
Vulnerable populations continue to have limited access to effective antimalarials. We are working to change this.
News
The Bathurst family and MMV join forces to set up a programme to support scientists from malaria-endemic countries.
07 July 2011
Funding for R&D in neglected diseases has risen yet declined for PDPs.
18 February 2011
